A randomized, double-blind, placebo-controlled study of single ascending doses of PTG-300 in normal healthy male subjects

Trial Profile

A randomized, double-blind, placebo-controlled study of single ascending doses of PTG-300 in normal healthy male subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2018

At a glance

  • Drugs PTG 300 (Primary)
  • Indications Beta-thalassaemia
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Protagonist Therapeutics
  • Most Recent Events

    • 18 Jun 2018 According to a Protagonist Therapeutics media release, data from this study were presented at the 23rd Congress of the European Hematology Association (EHA)
    • 14 Dec 2017 Status changed from recruiting to completed, according to a Protagonist Therapeutics media release.
    • 14 Dec 2017 Results, which included the successful completion of the study extension of two dose cohorts, published in a Protagonist Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top